Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR Background: A global named patient use (NPU) program for afatinib in patients with advanced/metastatic NSCLC who had progressed during prior therapy was conducted between May 2010 and January 2016 (Cappuzzo et al (2018) . Here we describe outcomes for patients at Asian centers, including 840 patients treated at centers in Taiwan. Method: Eligible patients had progressed after clinical benefit on prior erlotinib/ gefitinib and/or had an activating EGFR/HER2 mutation, had exhausted all other treatments, and were ineligible for afatinib trials. Patients received afatinib (starting dose: 30e50 mg/day). Dose modifications were guided by tolerability in individual patients. Time to treatment failure (TTF) was calculated from treatment initiation to discontinuation. Adverse event (AE) reporting was mandatory. Results: Data were collected from 2242 NSCLC patients in 10 Asian countries. Patients were heavily pretreated: 62% had received 2 prior chemotherapy lines, and for most, afatinib was at least 4 th -line therapy; almost all had received erlotinib/gefitinib (Table  1) . Among patients with known tumor biomarker status, 97% were EGFR mutation-positive (m+) (Taiwan subgroup: 100%). Median TTF was 7.6 months; EGFR m+, 7.2 months (Taiwan: 11.7 and 14.2 months respectively; Table 1 ). Median TTF was >12 months in patients with EGFR exon20 insertions (n¼23) and in those with HER2 mutations (n¼12) (also for the Taiwan subgroup). ORR was 24.4% (Taiwan: 4.3%): the disease control rates (DCR) were 78% and 97%, respectively ( Table 1 ). The most frequently reported AEs were rash and diarrhea; no safety signals were identified. Conclusion: This analysis from Asian countries in the afatinib NPU program revealed clinically meaningful TTF/ORR/DCR in this heavily pre-treated, refractory advanced NSCLC patient population, including activity in common and uncommon EGFR mutations. In Asian patients, TTF was numerically longer in patients with uncommon and HER2 mutations than in those with common EGFR mutations. The safety profile of afatinib was consistent with non-Asian centers. Thirty consecutively presenting patients with lung cancer to be treated with radiation therapy with or without chemotherapy. Study design: Prospective study of predictors of radiation pneumonitis in patients of carcinoma lung treated with radiation therapy with or without concurrent chemotherapy Endpoints: Primary endpoint: -1. All recruited patients underwent CRP, PFTs and 6-MWT before the start of treatment and subsequently at 3 and 6 months after treatment or at any time upon the development of radiation pneumonitis. 2. Patients were assessed at scheduled 4 weeks, 3 months and 6 months post completion of radiation therapy for clinics-radiological features of radiation pneumonitis. 3. At 4 weeks, assessment of symptoms and detailed clinical examination was done, no radiological tests were performed unless clinically warranted. Secondary endpoint: -The Mean Lung Dose (MLD) and other DVH parameters, calculated and documented during radiation treatment plan evaluation were correlated with the development of radiation pneumonitis. Results: On univariate analysis of dosimetric parameters, for development of grade 2 RP, total lung -PTV V5, total lung -PTV MLD (mean lung dose) and Ipsilateral lung -PTV V5 dose, and Gross tumour volume (GTV) were significant with p value of 0.010, 0.007 and 0.024 respectively. On Multivariate analysis, Total lung dose MLD and FEV1 (% predicted) were significantly associated with the development of grade 2 RP with p value of 0.048 and 0.040 respectively. Conclusion: Radiation pneumonitis occurred within three months of completing radiation therapy. There is significant loss of pulmonary function in patients who developed radiation pneumonitis. Pre-treatment value of pulmonary function test are important for predicting Radiation pneumonitis. We concluded that FEV1 % predicted value of less than 63.5 % is significant. Mean lung dose of total lung -PTV is also significant in predicting Radiation pneumonitis. We concluded that patients receiving more than 17.35 Gy as mean lung dose are prone to develop radiation pneumonitis. Location of tumour in lower lobe Gross tumour volume had a significant association with development of radiation pneumonitis. Keywords: lung cancer, nsclc, Pulmonary function test, Radiation pneumonitis
